Supply of CAR-T preparations (axicabtagene ciloleucel, lisocabtagene maraleucel)
Original notice title
Poland – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – DZP.242.281.2026 -Dostawa produktów leczniczych – preparaty CAR-T [Axicabtagene ciloleucel, Lisocabtagene maraleucel]
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
25 / 100
Risk factors
No estimated value disclosed; may indicate low budget or hidden constraints.
Structured data indicates EU funding, XML indicates no EU funds. Could affect contract terms or audit requirements.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 2 lots
- Duration 12 MONTH
- Supply of CAR-T medicinal products: Axicabtagene ciloleucel (Lot 1) and Lisocabtagene maraleucel (Lot 2).
- Delivery to Wrocław, Poland.
Show full summary
Open tender by Uniwersytecki Szpital Kliniczny we Wrocławiu for supply of CAR-T medicinal products: Axicabtagene ciloleucel (Lot 1) and Lisocabtagene maraleucel (Lot 2). Two lots, each for one task. Award based solely on lowest price. Duration 12 months. No financial or technical eligibility conditions required beyond standard business registration and, for pharmaceutical wholesalers, a permit from the Chief Pharmaceutical Inspector. Estimated value not disclosed. EU funding flag inconsistent between structured data (true) and XML (no EU funds). Language of procedure: Polish. Deadline for submission: 2026-07-27 10:00 Warsaw time.
Risks
No estimated value disclosed; may indicate low budget or hidden constraints.
Structured data indicates EU funding, XML indicates no EU funds. Could affect contract terms or audit requirements.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Tenderers must be registered in KRS (Poland) or equivalent business register.
- Pharmaceutical wholesalers must hold a permit from the Chief Pharmaceutical Inspector under the Pharmaceutical Law.
Administrative
- Electronic submission via the procurement platform (platformazakupowa.pl).
Award Criteria
Lot 1
Lot 2
Buyer
Location
WROCŁAW, POL
Website
Buyer profile
Identifier
8981816856
Activity
Health
Lots (2)
LOT-0001
Position 1 - Axicabtagene ciloleucel
Supply of Axicabtagene ciloleucel (CAR-T therapy). One task. Duration 12 months. Place of performance: Wrocław, Poland.
PLN 0
Estimated value
Location
Duration
Category
Award Criteria
Deadline
Award details
Za ofertę najkorzystniejszą zostanie uznana oferta zawierająca najniższą cenę: „Cena” – C
Value note
Show original TED data
Original lot title
POZYCJA NR 1
Original TED description
POZYCJA NR 1 - Axicabtagene ciloleucel - 1 ZADANIE
LOT-0002
Position 2 - Lisocabtagene maraleucel
Supply of Lisocabtagene maraleucel (CAR-T therapy). One task. Duration 12 months. Place of performance: Wrocław, Poland.
PLN 0
Estimated value
Location
Duration
Category
Award Criteria
Deadline
Award details
Za ofertę najkorzystniejszą zostanie uznana oferta zawierająca najniższą cenę: „Cena” – C
Value note
Show original TED data
Original lot title
POZYCJA NR 2
Original TED description
POZYCJA NR 2 - Lisocabtagene maraleucel - 1 ZADANIE
Procurement Details
- Publication date
- 24 Jun 2026
- Languages
- Polish
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 435226-2026
Documents (1)
Similar tenders
Czechia – Specialised chemical products – DNS - chemikálie pro molekulární a buněčnou biologii
Bulgaria – Pharmaceutical products – Доставка на лекарствени продукти за нуждите на УМБАЛ "Царица Йоанна-ИСУЛ" ЕАД
Lithuania – Pharmaceutical products – Vaistų ir kitų farmacijos produktų pirkimas
Bulgaria – Pharmaceutical products – Доставка на лекарствени продукти за нуждите на ВМА и подчинените й структури
Lithuania-Kaunas: General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
25 / 100
Risk factors
No estimated value disclosed; may indicate low budget or hidden constraints.
Structured data indicates EU funding, XML indicates no EU funds. Could affect contract terms or audit requirements.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications